Financial Data and Key Metrics Changes - Total revenues for 2025 were approximately $3.2 million, an increase from $2.3 million in 2024, primarily driven by strong seed sales from the subsidiary Castera [9][26] - Research and development expenses for 2025 were approximately $4.8 million, down from $6.5 million in the same period last year, due to reduced R&D activities at Biomica and the discontinuation of operations at Canonic [10][27] - Total operating expenses for 2025 were approximately $7.7 million, significantly decreased from $11.1 million in the same period last year, attributed to reduced activity levels in subsidiaries [11][29] - The net loss for 2025 was approximately $7.7 million, compared to $9.8 million in the same period last year, reflecting decreased operating expenses and increased financing income [32] Business Line Data and Key Metrics Changes - Castera, the subsidiary responsible for seed sales, was the primary contributor to revenue growth, with revenues recognized for seed sales in 2025 [9][26] - Biomica is focused on completing its clinical trial expected in early 2026 and securing partners for its development programs, holding approximately $4 million in cash [17][21] - Laviv Bio's activities were largely sold to ICL, with a total consideration of $15.25 million, enhancing cash flow for Evogene [14] Market Data and Key Metrics Changes - The company is undergoing a strategic shift to maximize the value of Campus AI, focusing on AI-driven discovery and optimization in pharmaceuticals and agriculture [12][19] - The collaboration with Tel Aviv University aims to develop small molecule therapeutics targeting diseases caused by metabolite accumulation, leveraging Campus AI [13] Company Strategy and Development Direction - The strategic priorities include strengthening Campus AI, expanding collaborations in small molecule drug discovery, and streamlining operational expenses [12][19] - The company plans to establish a dedicated business development arm to accelerate growth in the pharmaceutical vertical and maintain strategic collaborations in agriculture [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the new strategic direction and the potential for increased investor interest as new collaborations are announced [40] - The company expects continued reductions in operating expenses in the third and fourth quarters of 2025 [42] Other Important Information - Evogene raised $4.4 million through an at-the-market facility, enhancing its financial position and providing an operational runway of approximately 18 months [18] - The company is focusing on operational discipline and long-term value creation, with plans to present its updated corporate strategy at industry conferences [23] Q&A Session Summary Question: How much caster seed inventory do you have today, both finished and expected to be finished after the harvest? - The company has a few hundred tons of castor seed ready for sale and plans to utilize its seeds for cultivation to sell grain to partners [35][36] Question: What steps need to occur before you can announce a castor oil business? - The company is currently focused on grain cultivation and selling grain to partners, with existing crushing oil factories eager for castor grain [38] Question: The stock is still low. When will it start going up? - Management indicated that they cannot control the stock market but are finalizing a new company presentation and plan to announce new collaborations that could positively impact stock value [39][40] Question: How representative are operating expenses in Q2 2025 for going forward operations? - Management confirmed that all cost reductions are fully reflected in the numbers, with expectations for continued expense declines [42] Question: What was revenue in Q2 2025? How should we think about peak sales given recent results? - The revenue in Q2 2025 was primarily from Castera, with expectations for future sales growth as the company engages with multiple partners [43][44] Question: For Campus AI platform, what catalyst milestones should we expect in the next twelve to eighteen months? - The company anticipates announcements of new collaborations and breakthroughs in technology development as key milestones [46][49]

REHOVOT, Israel, July 8, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company utilizing cutting-edge artificial intelligence and predictive biology to drive innovation in life-science product development, today announced the successful completion and closing of the previously disclosed transaction involving the divestiture of the majority of the activities and assets of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd. (NYSE: ICL) (TASE: ICL). ...

Core Insights - Evogene Ltd. has completed its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud, addressing the challenge of identifying novel small molecules for pharmaceutical and agricultural applications [1][6] - The new model enhances the capabilities of ChemPass AI by enabling simultaneous consideration of multiple complex product requirements, which is crucial for innovation and securing intellectual property [3][4] Company Developments - The foundation model achieves approximately 90% precision in novel molecule designs, a significant improvement over traditional methods which have around 29% precision [4] - The model is built on a dataset of approximately 38 billion molecular structures and utilizes Google Cloud's advanced AI infrastructure, ensuring scalability for future enhancements [5] - Evogene is already working on version 2.0 of its generative AI model, focusing on enhanced flexibility for multi-parameter optimization tailored to specific therapeutic and agricultural needs [6] Industry Implications - The generative AI model is expected to reduce late-stage failures in pharmaceutical R&D and facilitate the development of effective, sustainable, and proprietary agricultural chemicals [6] - The model's ability to create novel, patentable molecules positions Evogene to significantly impact drug discovery and agricultural product development [3][6]

Company Overview - EverGen Infrastructure Corp. is a Canadian renewable energy company focused on waste-to-energy projects and establishing a renewable natural gas infrastructure platform across Canada [2] - Since its incorporation in May 2020, EverGen has been acquiring, developing, owning, operating, and consolidating a portfolio of compost, renewable natural gas, waste-to-energy, and related sustainable infrastructure projects [2] - The company currently operates two renewable natural gas production facilities: Fraser Valley Biogas in Abbotsford, British Columbia, and Grow the Energy Circle Ltd. in Lethbridge, Alberta, along with two composting facilities: Pacific Coast Renewables and Sea to Sky Soils, both located in British Columbia [2] Industry Context - The Canadian Climate Investor Conference (CCIC) is hosted by the Toronto Stock Exchange and TSX Venture Exchange, aimed at bringing together clean technology and renewable energy companies with climate-conscious investors [3] - The conference focuses on showcasing clean technology investments and aims to democratize the ability for investors to participate in the growing clean technology ecosystem [4] - The event is designed to facilitate the sharing of ideas and accelerate the deployment of capital necessary for building a sustainable future in Canada [3][4] Event Participation - EverGen Infrastructure Corp. will be presenting at the 2025 Canadian Climate Investor Conference on June 11, 2025, at the Arcadian Court in Toronto, Ontario [1]

Core Viewpoint - EverGen Infrastructure Corp. has successfully closed a Private Placement transaction with Ask America, LLC, raising CAD$5,000,000 and undergoing a significant Change of Management [1][2][6]. Private Placement - The first tranche of the Private Placement involved the issuance of 8,333,333 Common Shares at a price of $0.60 per share, resulting in gross proceeds of CAD$5,000,000 [2]. - The Company anticipates additional tranches of the Private Placement, potentially raising up to CAD$7,000,000 in total [2]. - The Common Shares from the Private Placement are subject to a four-month hold period under applicable securities laws [3]. Change of Management - A majority of the executive officers and directors resigned, with a new management team appointed, including Chase Edgelow as CEO and Ron Green as COO [6]. - The new Board of Directors consists of Chase Edgelow, Varun Anand, Blake Almond, and Mischa Zajtmann, and these changes were approved by a majority of shareholders [6]. Shareholder Impact - Following the Private Placement, Ask America holds approximately 37% of the issued and outstanding Common Shares on a non-diluted basis and about 34% on a fully diluted basis [8]. - Prior to the Private Placement, Ask America did not own any securities of the Company [8]. Equity Incentive Grant - The Company granted 1,500,000 stock options, 150,000 deferred share units, and 350,000 restricted share units to certain directors and officers as part of its equity incentive plan [10]. - The stock options have an exercise price of $0.60 per Common Share and a seven-year term, with vesting occurring over three years [10]. Company Overview - EverGen Infrastructure Corp. is a Canadian renewable natural gas infrastructure platform focused on combating climate change and promoting sustainable energy solutions [11]. - The Company is headquartered on the West Coast of Canada and is involved in acquiring, developing, and operating renewable energy projects [11].

Core Points - EverGen Infrastructure Corp. has received final approval from the TSX Venture Exchange for a purchase and sale agreement related to the disposition of a property in Abbotsford, B.C. for a total purchase price of CAD$2,620,000 [1][2] - The transaction includes a deferred payment of CAD$870,000 to be paid upon the completion of the sale of a separate property owned by the purchasers, expected by the end of May 2025 [2] - The vendor has leased a portion of the property back from the purchasers for up to 20 years, with an annual rent of CAD$186,000, reduced to CAD$124,236 while the deferred amount is outstanding [3] - The transaction is classified as a related party transaction due to the involvement of James Betts, the Chief Operating Officer of the company, and the company is relying on exemptions from certain requirements under Multilateral Instrument 61-101 [4] - EverGen is also updating on a share purchase and reorganization agreement with Ask America, LLC, anticipating gross proceeds of up to CAD$7,000,000, with all material conditions satisfied prior to closing [5] - EverGen is focused on renewable energy projects in Canada and aims for continued growth across North America and beyond [6]

Core Insights - Evogene Ltd. is set to release its financial results for Q1 2025 on May 21, 2025, followed by a conference call to discuss these results [1][2] Company Overview - Evogene Ltd. is a computational biology company that utilizes big data and artificial intelligence to innovate life-science product development, aiming to enhance success rates while minimizing development time and costs [3] - The company has established three unique technology engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different core components: microbes, small molecules, and genetic elements respectively [4] Subsidiaries and Focus Areas - Evogene operates four subsidiaries: 1. Biomica Ltd. focuses on microbiome-based therapeutics for human disorders using MicroBoost AI [6] 2. Lavie Bio Ltd. develops microbiome-based agricultural biologicals powered by MicroBoost AI [6] 3. AgPlenus Ltd. is engaged in developing next-generation agricultural chemicals for sustainable crop protection using ChemPass AI [6] 4. Casterra Ag Ltd. specializes in high-yield castor seed varieties for biofuel and other industries, utilizing GeneRator AI [6]

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws. VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) is pleased to announce that it has entered into a share purchase and reorganization agreement (the “Agreement”) on April 22, 2025, with Ask America, LLC (the “Purchaser”), an arm’s length lim ...

Financial Performance and Market Conditions - The appreciation of the NIS against the U.S. dollar was (0.6%), (3.1%), and (13.2%) for the years ended December 31, 2024, 2023, and 2022, respectively, which may negatively affect financial results [154]. - The Israeli annual rate of inflation was 5.3%, 3.0%, and 3.2% for the years ended December 31, 2022, 2023, and 2024, respectively [154]. - The market price of the company's ordinary shares has declined since the reverse split, affecting total market capitalization [171]. Grants and Royalties - The company received approximately $9.4 million in royalty-bearing grants from the Israeli Innovation Authority, with a repayment of approximately $3.9 million in royalties [158]. - The company is committed to pay royalties at a rate of 3.0% - 4.0% on sales proceeds from products developed under IIA programs [157]. Nasdaq Compliance and Corporate Governance - On October 31, 2022, the company received a notification from Nasdaq for non-compliance with the minimum bid price requirement of $1.00 per share [166]. - The company was granted an additional 180-day grace period until October 30, 2023, to regain compliance with Nasdaq listing requirements [167]. - A reverse share split of 1-for-10 was executed on July 24, 2024, to temporarily regain compliance with Nasdaq listing standards [169]. - Being a public company in both the U.S. and Israel may strain resources and distract management, increasing legal and financial compliance costs [175]. - The company follows Israeli corporate governance practices instead of Nasdaq requirements, potentially providing less protection to investors [178]. - Loss of foreign private issuer status could significantly increase compliance costs and regulatory burdens [179]. Legal and Regulatory Challenges - The company may face challenges in transferring know-how and manufacturing rights outside of Israel due to restrictions from IIA grants [158]. - The company may encounter difficulties in enforcing U.S. judgments in Israel or asserting U.S. securities law claims due to its incorporation in Israel [159]. - The company currently utilizes U.S. reporting standards but may face increased compliance costs if parallel reporting obligations in Israel and the U.S. are imposed [174]. - The company incurs significant accounting, legal, and other expenses related to reporting requirements under the Exchange Act and Sarbanes-Oxley Act, which may divert management's attention from business operations [176]. - As a foreign private issuer, the company is exempt from certain U.S. regulations, which may reduce the frequency and scope of information available to investors [177]. Tax Implications - U.S. shareholders owning at least 10% of the company's ordinary shares may face adverse federal income tax consequences [180]. - The company believes it was not a Passive Foreign Investment Company (PFIC) for 2024, but there is a risk of being classified as such in 2025, which could lead to adverse tax consequences for U.S. shareholders [182]. Internal Control and Reporting - Failure to maintain effective internal control over financial reporting could adversely affect the price of the company's ordinary shares [184].

Financial Data and Key Metrics Changes - Total revenues for 2024 reached approximately $8.5 million, an increase from approximately $5.6 million in 2023, primarily driven by AgPlenus revenues from collaboration with Bayer and increased Casterra seed sales [14][56] - Q4 2024 total revenues were approximately $1.6 million, compared to $0.6 million in Q4 2023, mainly due to increased Casterra seed sales [15][56] - Total R&D expenses for 2024 were approximately $16.6 million, down from $20.8 million in 2023, with Q4 2024 R&D expenses at approximately $3.4 million, down from $5.5 million in Q4 2023 [16][57] - General and administrative expenses for 2024 increased to approximately $7.4 million from $6.1 million in 2023, influenced by one-time expenses related to fundraising [18][59] - The net loss for 2024 was approximately $18.1 million, a decrease from $26 million in 2023, with Q4 2024 net loss at approximately $5,000, down from $7.3 million in Q4 2023 [61][62] Business Line Data and Key Metrics Changes - Casterra delivered approximately 215 tons of castor seeds in 2024, with only 76 tons delivered in Q4 2024, but 250 tons delivered in February 2025 alone, indicating a resolution of previous production bottlenecks [15][20] - Lavie Bio signed a new collaboration agreement with Syngenta in February 2024 and reported advancements in biostimulants and bio fungicides throughout 2024 [23][24] - AgPlenus signed a collaboration agreement with Bayer in February 2024 and achieved milestones with Corteva for novel herbicides [25][26] Market Data and Key Metrics Changes - Casterra is focusing on expanding its seed production in Africa and Brazil, with significant demand for castor grain in both markets [21][70] - The company is exploring new commercial opportunities in the castor oil industry, leveraging its unique seed varieties and advanced growth protocols [48][49] Company Strategy and Development Direction - The company aims to position itself as a leader in life science product development, integrating advanced computational technologies with life sciences [28][30] - A targeted business strategy is in place to maximize potential while minimizing risk through collaborative partnerships for product development [32][34] - The focus for 2025 includes enhancing ChemPass AI for drug discovery and creating exit events for subsidiaries to inject funds into the company [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's potential to unlock significant value through its subsidiaries and advanced computational capabilities [11][12] - The company is committed to a capital-efficient model and anticipates achieving strategic goals in 2025 [12][34] Other Important Information - The company established an expense reduction plan expected to reduce expenses by approximately 30% by Q1 2025 [17] - The company is currently in discussions for potential collaborations and partnerships in the drug discovery space [43][46] Q&A Session Summary Question: Expected cash burn for 2025 - Expected cash burn for 2025 is projected to be between $6 million to $7 million, excluding cash from potential subsidiary sales [64] Question: Status of exit efforts for subsidiaries - Exit efforts are being prioritized, but specific details cannot be disclosed at this time [66][68] Question: Initial sales expectations in Brazil for Casterra - Initial sales in Brazil are expected to come from both seed and grain sales, with a focus on seed sales in 2025 [69][72] Question: Base case sales goal for Yalos in spring wheat and soybeans - Specific sales goals were not disclosed, but there is growing interest in Yalos for soybean growers due to higher margins [73][75] Question: Magnitude of castor sales in 2025 - Q1 2025 is expected to be a strong quarter for Casterra, with 250 tons already delivered, but not necessarily the largest quarter for the year [76][79] Question: Structure of potential joint venture for oil production - The company is currently responsible for seed production and cultivation, with plans to sell grain under offtake agreements, while not taking on responsibilities for oil production in 2025 [83][85] Question: Expense levels for 2025 - Expense levels in Q4 2024 are expected to reflect similar levels in 2025, with potential further declines anticipated [87][90]